This dataset is a directory of the different pharmaceutical companies in the United States and the European Union. It includes the company’s specialization, physical address, contact details, email and website links.

Based on revenues latest available as of 2024, Johnson & Johnson was the top ranked pharmaceutical company in the United States. Johnson & Johnson generated over 85 billion U.S. dollars worldwide, which is around 25 billion U.S. dollars more than the next ranked U.S. pharmaceutical company, Pfizer. However, Johnson & Johnson's total revenue includes also sales from their medical device and consumer health divisions, while Pfizer is a pure-play biopharmaceutical company.

Branded and generic drugs: What are the differences? Patented products marketed by pharmaceutical companies are referred to as branded. The protection of the patent means that the company, which has spent a large amount of money researching and developing the product, can exclusively sell the drug – often at a high price to recoup its investment. Once the patent expires, other companies may produce generic versions of the product, which contain the same key ingredients.

This statistic shows the 2024 ranking of the top 10 biotech and pharmaceutical companies worldwide, based on net income. U.S.-based company Johnson & Johnson was ranked first with a net income of 16.4 billion U.S. dollars. Biotech and pharmaceutical companiesJohnson & Johnson and Merck & Co., both based in the United States, are among the world’s largest biotechnology and pharmaceutical companies based on their net incomes of approximately 16.4 billion U.S. dollars and 13.7 billion U.S. dollars, respectively, as of 2024. Johnson & Johnson generated some 86 billion U.S. dollars of revenue in 2023. Pfizer had record-high annual revenues during the COVID-19 vaccination campaign, reaching 100 billion U.S. dollars in 2022.

Story of a former blockbuster Lyrica was once one of Pfizer’s most successful products. It is an anticonvulsant for neuropathic pain and is also used as therapy for partial seizures. In the EU and in Russia, Lyrica has also been approved to treat general anxiety disorder. In 2017, this prescription medication generated some five billion U.S. dollars in revenue.

Success.ai’s Pharma Data for the Global Pharmaceutical Industry provides a robust dataset tailored for businesses looking to connect with pharmaceutical companies, decision-makers, and key stakeholders worldwide. Covering pharmaceutical manufacturers, research organizations, biotech firms, and distributors, this dataset offers verified SIC codes, firmographic details, and contact information for executives and operational leads.

With access to over 170 million verified professional profiles and 30 million company profiles, Success.ai ensures your outreach, market research, and business development strategies are driven by reliable, continuously updated, and AI-validated data. Supported by our Best Price Guarantee, this solution is essential for navigating the competitive global pharmaceutical landscape.

Why Choose Success.ai’s Pharma Data?

1. Verified Contact Data for Precision Outreach

   • Access verified work emails, phone numbers, and LinkedIn profiles of pharmaceutical executives, R&D leads, compliance officers, and procurement managers.
   • AI-driven validation ensures 99% accuracy, optimizing your campaigns and improving communication efficiency.

2. Comprehensive Coverage of the Global Pharmaceutical Sector

   • Includes profiles of pharmaceutical companies, biotech firms, contract manufacturing organizations (CMOs), and distributors across North America, Europe, Asia, and other major markets.
   • Gain insights into regional pharmaceutical trends, product pipelines, and market dynamics unique to global markets.

3. Continuously Updated Datasets

   • Real-time updates reflect leadership changes, mergers, product launches, and regulatory compliance shifts.
   • Stay aligned with the fast-paced pharmaceutical industry to capitalize on emerging opportunities and maintain relevance.

4. Ethical and Compliant

   • Adheres to GDPR, CCPA, and other global privacy regulations, ensuring responsible use of data and compliance with legal standards.

Data Highlights:

• 170M+ Verified Professional Profiles: Engage with decision-makers, R&D specialists, and operational leaders in the pharmaceutical industry worldwide.
• 30M Company Profiles: Access detailed firmographic data, including company sizes, revenue ranges, and geographic footprints.
• Verified SIC Codes: Understand industry classifications and product specializations to refine your targeting strategies.
• Leadership Contact Details: Connect with CEOs, COOs, medical directors, and regulatory managers influencing pharmaceutical operations.

Key Features of the Dataset:

1. Decision-Maker Profiles in Pharmaceuticals

   • Identify and engage with professionals overseeing R&D, clinical trials, supply chains, and regulatory compliance.
   • Target leaders responsible for drug development, vendor selection, and market entry strategies.

2. Advanced Filters for Precision Targeting

   • Filter companies by industry segment (biotech, generic pharmaceuticals, vaccines), geographic location, or revenue size.
   • Tailor campaigns to align with specific needs such as drug pipeline acceleration, production scaling, or market expansion.

3. SIC Codes and Firmographic Insights

   • Access verified SIC codes and detailed company profiles to understand market focus, operational scale, and specialization areas.
   • Use firmographic data to prioritize high-value targets and align product offerings with market demands.

4. AI-Driven Enrichment

   • Profiles enriched with actionable data allow for personalized messaging, highlight unique value propositions, and improve engagement outcomes with pharmaceutical stakeholders.

Strategic Use Cases:

1. Sales and Lead Generation

   • Offer technology solutions, research tools, or contract services to pharmaceutical manufacturers, R&D facilities, and distribution networks.
   • Build relationships with procurement teams and compliance officers responsible for vendor approvals and operational excellence.

2. Market Research and Product Development

   • Analyze global pharmaceutical trends, drug approval patterns, and regulatory frameworks to guide product innovation and market entry strategies.
   • Identify high-growth regions and emerging therapeutic areas to focus your resources effectively.

3. Partnership and Supply Chain Development

   • Connect with pharmaceutical companies seeking contract manufacturing, raw material sourcing, or distribution partnerships.
   • Foster alliances that streamline production, ensure quality, and accelerate time-to-market.

4. Regulatory Compliance and Risk Mitigation

   • Engage with regulatory officers and compliance managers overseeing adherence to local and international pharmaceutical standards.
   • Present solutions for documentation, reporting, and risk management to ensure compliance and operational efficiency.

Why Choose Success.ai?

1. Best Price Guarantee
   ...

This statistic shows the ranking of the global top 10 biotech and pharmaceutical companies worldwide, based on revenue. The values are based on a 2024 database. U.S. pharmaceutical company Pfizer was ranked first, with a total revenue of around 87 billion U.S. dollars. Biotech and pharmaceutical companiesPharmaceutical companies are best known for manufacturing pharmaceutical drugs. These drugs have the aim to diagnose, to cure, to treat, or to prevent diseases. The pharmaceutical sector represents a huge industry, with the global pharmaceutical market being worth over 1.5 trillion U.S. dollars. The best known top global pharmaceutical players are Pfizer, Merck and Johnson & Johnson from the U.S., Novartis and Roche from Switzerland, Sanofi from France, etc. Most of these companies are involved not only in pure pharmaceutical business, but also manufacture medical technology and consumer health products, vaccines, etc. For example, Johnson & Johnson makes most of its revenues through medical devices, diagnostics and consumer health products. There are both pure play biotechnology companies as well as pharmaceutical companies which among other products also produce biotech products within their biotechnological divisions. Most of the leading global pharmaceutical companies have biopharmaceutical divisions. Although not a pure play biotech firm, Roche from Switzerland is among the companies with the largest revenues from biotechnology products worldwide. In contrast, California-based company Amgen was one of the world’s first large pure play biotech companies. Biotech companies use biotechnology to generate their products, most often medical drugs or agricultural genetic engineering. The latter segment is dominated by companies like Bayer CrpScience and Syngenta. The United Nations Convention on Biological Diversity defines biotechnology as follows: "Any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use." In fact, biotechnology is thousands of years old, used in agriculture, food manufacturing and medicine.

This dataset contains the Applications part to build the Drugs@FDA database. Drugs at FDA is a database of FDA Approved Drug Products available on the FDA official website. It provides information of drug (generic) name, active ingredient, form and strength available, FDA application number, label info, dosage form or route, marketing status and pharmaceutical company as well as patient information, approval letters, review and other facts for drugs approved after 1997.

This medical dataset contains the Application Submission part to build the Drugs@FDA database from the Food and Drug Administration (FDA) Approved Drug Products available on their official website. It provides information on drug (generic) name, active ingredient, form and strength available, FDA application number, label info, dosage form or route, marketing status, and pharmaceutical company as well as patient information, approval letters, review and other facts for drugs approved after 1997.

This statistic gives you the list of top global pharmaceutical companies based on the enterprise value for the year 2022, in billion U.S. dollars. AbbVie had an enterprise value of nearly 340 billion U.S. dollars, which was around 2.6 percent higher than the previous year.

China Pharmaceutical: YoY: Gross Industrial Output: Year to Date data was reported at 21.173 % in Dec 2012. This records an increase from the previous number of 20.239 % for Sep 2012. China Pharmaceutical: YoY: Gross Industrial Output: Year to Date data is updated monthly, averaging 19.740 % from Jan 2003 (Median) to Dec 2012, with 73 observations. The data reached an all-time high of 29.860 % in Sep 2011 and a record low of 12.700 % in Jun 2004. China Pharmaceutical: YoY: Gross Industrial Output: Year to Date data remains active status in CEIC and is reported by National Bureau of Statistics & YYTJ. The data is categorized under China Premium Database’s Pharmaceutical Sector – Table CN.RTC: Pharmaceutical Industry.

China Pharmaceutical: Sales Revenue: Year to Date data was reported at 1,615,180.000 RMB mn in Jun 2022. This records an increase from the previous number of 1,053,300.000 RMB mn for Apr 2022. China Pharmaceutical: Sales Revenue: Year to Date data is updated monthly, averaging 643,313.916 RMB mn from Jan 2002 (Median) to Jun 2022, with 215 observations. The data reached an all-time high of 3,304,930.000 RMB mn in Dec 2021 and a record low of 32,828.985 RMB mn in Feb 2002. China Pharmaceutical: Sales Revenue: Year to Date data remains active status in CEIC and is reported by National Bureau of Statistics & YYTJ. The data is categorized under Global Database’s China – Table CN.RTC: Pharmaceutical Industry. Starting from 2019, sales revenue includes income from principal and other business.

161 Active Global Pharmaceutical industry suppliers, manufacturers list and Global Pharmaceutical industry exporters directory compiled from actual Global export shipments of Pharmaceutical industry.

In 2022, U.S.-based company Tempus was the world's leading data processor for drug development based on investments. Investments for the company stood at 1.3 billion U.S. dollars that year. Tempus uses advanced data analytics and artificial intelligence/machine learning for drug discovery and development.

Graph and download economic data for Producer Price Index by Industry: Pharmaceutical and Medicine Manufacturing (PCU3254132541) from Dec 2003 to Feb 2025 about medicines, pharmaceuticals, manufacturing, PPI, industry, inflation, price index, indexes, price, and USA.

The Report Covers Global Drug Discovery Informatics Market Share & Size and It is Segmented by Function (Sequencing and Target Data Analysis, Docking, Molecular Modelling, Libraries and Database Preparation, and Others), End-User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROS), Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Provides the Value (in USD) for the Above Segments.

These supplementary materials represent a dataset in the form of a quantitative database of antibiotics' developers, and a partial collection of semi-structured interviews, collected and analyzed in the research article "Beyond resistance: How can alternative innovation models develop and enhance global access to new antibiotics?". This article is one of the outcomes of the "New Business Models for Pharmaceutical Innovation and Global Access to Medicines" research project, conducted at the Global Health Center, within the Geneva Graduate Institute. The dataset contains a quantitative dataset of antibiotics' developers and their characteristics, as well as 6/11 interviews collected and used in this article, which are published with the informed consent of the interviewees.

Knowledge Management in Pharmaceutical Market size was valued at USD 1.5 Billion in 2023 and is projected to reach USD 2.63 Billion by 2030, growing at a CAGR of 8.00% during the forecast period 2024-2031.

Global Knowledge Management in Pharmaceutical Market Drivers

The market drivers for the Knowledge Management in Pharmaceutical Market can be influenced by various factors. These may include:

• Regulatory Compliance: Businesses in the pharmaceutical industry work in a highly regulated setting. Clinical trial data, medication development records, and regulatory submissions are just a few examples of the vital material that effective knowledge management systems organize and manage to help guarantee regulatory compliance.
• Rapid Technological Advancements: With the introduction of artificial intelligence (AI), big data analytics, and machine learning, the pharmaceutical sector is constantly changing. Knowledge management systems make it easier to integrate and use these technologies to boost innovation, expedite workflows, and enhance decision-making.
• Growing Complexity of Drug Development: The processes involved in developing new drugs are getting more intricate and expensive. Pharmaceutical businesses can expedite drug discovery, development, and commercialization by managing and utilizing large amounts of scientific and clinical data through the use of knowledge management.
• Globalization and Collaboration: When working on drug development initiatives, pharmaceutical corporations frequently collaborate with research groups, universities, and other business partners. Knowledge management systems make collaborative research more efficient by offering a central location for knowledge exchange and access, encouraging creativity, and boosting productivity.
• Growing Significance of Personalized Medicine: Pharmaceutical companies must gather, examine, and handle vast amounts of patient data, genetic data, and clinical results as a result of the shift to personalized medicine. Knowledge management systems facilitate the amalgamation of heterogeneous data sources to bolster personalized medical endeavors, including the identification of biomarkers, patient classification, and the creation of tailored therapeutic approaches. The pharmaceutical sector is characterized by intense competition and cost pressures, as companies strive to get novel drugs to the market in a timely and economical manner. From discovery to commercialization, knowledge management supports pharmaceutical companies in maximizing resources, reducing risks, and enhancing operational effectiveness.
• Risk management and patient safety: It is crucial to guarantee the security and effectiveness of pharmaceutical products. Pharmaceutical businesses use knowledge management systems to monitor post-market surveillance data to maintain patient safety and to identify, assess, and minimize risks related to medication research and manufacturing processes.
• Demand for Evidence-Based Decision Making: In the areas of drug development, regulatory approval, and patient care, stakeholders in the healthcare industry, such as payers, regulators, healthcare providers, and patients, are calling for more and more evidence-based decision-making. Pharmaceutical businesses can produce, evaluate, and share scientific evidence to help educated decisions and enhance patient outcomes by using knowledge management systems.

In 2022, Biogen generated almost 350 thousand U.S. dollars’ worth of net profit per employee, which ranked the company second among the global top 15 pharmaceutical companies. Net profit per employee data can be used as an indicator to gauge how profitable a company (or industry) is.

Biogen

Biogen is a biotechnology & pharmaceutical company, based in Massachusetts, United States, specialized in developing medical solutions for neurological and neurodegenerative diseases. In 2022, Biogen had an average of over 8,700 people employed.

Pharmaceutical giants

Today, some of the largest corporations in the pharma industry include Johnson & Johnson, Novartis, Pfizer, and Roche, to name a few. Based on market capitalization worldwide, Eli Lilly led the list as of October 2023, with a market cap of roughly 500 billion U.S. dollars. In terms of 2022 prescription sales numbers, Roche stood in sixth place with about 48 billion U.S. dollars, while placed first in the R&D rankings, spending almost 15 billion dollars on research and development.

The top 50 pharmaceutical companies by prescription sales in 2023 – and their research and development (R&D) spending – included big names such as Johnson & Johnson, Novartis, and AbbVie. During that year, Johnson & Johnson's Rx sales were approximately 53.5 billion U.S. dollars. Thus, the American pharma giant was both the largest pharmaceutical company based on pure pharma revenue worldwide and the second ranked pharmaceutical company based on R&D spending. Johnson & Johnson spent 14.8 billion U.S. dollars on R&D in that year.

Pharmaceutical R&D spending Research and development in the pharmaceutical industry involves the identification and development of compounds used to make new drugs. The pharmaceutical industry has the largest percentage of spending attributable to R&D among all industries. Research and development spending in the pharmaceutical industry around the world is increasing over time. However, there have been variations in the growth of research and development spending with a peak during the pandemic years 2020 and 2021.

New pharmaceutical products The goal of R&D is to produce new drugs and compounds. Globally, the U.S. pharmaceutical industry created the largest number of new drugs and compounds between 2018 and 2022, followed by Europe. Among U.S. pharmaceutical companies, there are various levels of success for new drugs depending on the phase of development. The data shows that between phase I and II alone, already over half of all drugs are failing.

12960 Active Global Pharmaceutical suppliers, manufacturers list and Global Pharmaceutical exporters directory compiled from actual Global export shipments of Pharmaceutical.

Study design We conducted a cross-sectional study to quantify the number and describe the characteristics of prescription drugs on the Canadian market as of August 23, 2022 with a patient support program defined as services (including but not limited to financial assistance) offered to patients prescribed a specific drug and initiated and funded by the manufacturer. We then conducted a structured content analysis of web-based sources to understand the types and range of supports provided to patients through these programs. We chose to rely exclusively on publicly available data sources to both identify and describe manufacturer-sponsored patient support programs as these are sources currently available to patients when making program enrolment decisions and policymakers seeking to understand the extent and impact of this model of care. Sampling frame Because the European Medicines Association defines a patient support program as services for a specific drug offered by the company holding the marketing authorization, we first sought to identify all drug companies with currently marketed, prescription products in Canada. Between June 27, 2022 and August 23, 2022, two investigators independently extracted the names of all member companies listed on the websites of the three main trade associations for the Canadian pharmaceutical industry (Innovative Medicines Canada, representing the research-based pharmaceutical industry; BIOTECanada, representing the biotechnology industry; and the Canadian Generic Pharmaceutical Association, representing generic drug manufacturers). Because trade association membership is voluntary, we supplemented this list with non-member drug manufacturers identified in previous research. Using the Health Canada Drug Product Database,two investigators independently screened the list of companies and included those with marketed, prescription products and excluded companies that were not drug manufacturers (e.g., law firms) or without currently marketed prescription drugs (e.g., products under development). Discrepancies were resolved through discussion or adjudication by a third author. Sample and variables Using the Health Canada Drug Product Database, one investigator searched each identified drug manufacturer and extracted the product and active ingredient name(s) for all marketed, prescription drugs. We counted a single “drug” as all dosages, formulations, or routes of administration with the same active ingredients and manufacturer since industry patient support programs are brand-specific and do not typically differentiate among these factors. We selected variables that reflect known characteristics of drugs that may be associated with having a patient support program, and for which data were publicly available. One investigator also extracted Schedule D (biologic) status, route(s) of administration, and Level 1 Anatomical Therapeutic Chemical (ATC) code from the Drug Product Database and Product Monograph and identified whether the drug had Orphan Drug Status using the searchable United States database. On the basis of type of Health Canada regulatory review (i.e. innovator or subsequent entry), clinical expertise, and knowledge about the manufacturer, two investigators independently identified the brand status of each drug as brand (i.e. “innovator” products first to market); branded generic (i.e. “subsequent entry” products which are bioequivalent or biosimilar to an existing product on the market, but given a proprietary name); or generic (i.e. “subsequent entry” products which are bioequivalent to an existing product on the market). We classified biosimilars as branded generics. We resolved discrepancies through discussion, and/or adjudication by a third author. Identifying patient support programs and their characteristics Our primary outcome was whether a sampled drug had an associated manufacturer-sponsored patient support program. We defined a patient support program as any combination of services or resources related to medication access, administration, adherence, education, storage, or disposal for patients prescribed a specific product and initiated, sponsored and/or operated by the company holding the product’s marketing authorization. We distinguished patient support programs from “patient assistance programs,” excluding programs that exclusively provided financial assistance (e.g., coupons, co-pay coverage, etc.); expanded or compassionate access programs; risk management programs outlined in the Product Monograph (initiated by the regulator rather than the manufacturer); and programs delivered solely for a clinical study. Two investigators independently performed structured searches on Google (“[company name] AND patient support program AND Canada” and “[drug brand name] AND patient support program AND Canada”) to identify industry sponsored patient support programs in Canada and resolving discrepancies through discussion. Using Zotero, a reference management...